A new generation of
artificial heart valves
- free of anticoagulant
- for life
Novostia endeavors to advance its technology to clinical trials and regulatory approvals to improve the quality of life of millions of people worldwide suffering from aortic and mitral valve disease (*)
An answer to a large unmet need worldwide
For patients of any age, including children
Design for the aortic & mitral valves
"I have been impressed by the Lapeyre-Triflo valve and look forward to starting first-in-man clinical trials.
This valve has the potential to benefit thousands of patients, especially young people."
Prof. Thierry Carrel, M.D.
University Hospital of Bern, Switzerland
(*) Caution: Novostia technology is an investigational device not yet approved for sale